Article
Assessment for the timing of comprehensive genomic profiling tests in patients with advanced solid cancers.
Cancer science - 1 Aug 2023
Hagio Kanako, Kikuchi Junko, Takada Kohichi, Tanabe Hiroki, Sugiyama Minako, Ohhara Yoshihito, Amano Toraji, Yuki Satoshi, Komatsu Yoshito, Osawa Takahiro, Hatanaka Kanako C, Hatanaka Yutaka, Mitamura Takashi, Yabe Ichiro, Matsuno Yoshihiro, Manabe Atsushi, Sakurai Akihiro, Ishiguro Atsushi, Takahashi Masato, Yokouchi Hiroshi, Naruse Hirohito, Mizukami Yusuke, Dosaka-Akita Hirotoshi, Kinoshita Ichiro
Abstract excerpt
Comprehensive genomic profiling (CGP) tests have been covered by public insurance in Japan for patients with advanced solid tumors who have completed or are completing standard treatments or do not have them. Therefore, genotype-matched drug candidates are often unapproved or off-label, and improving clinical trial access is critical, involving the appropriate timing of CGP tests. To address this issue, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.